We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Single-Cell Analysis Elucidates Mutation Patterns in Myeloid Malignancies

By LabMedica International staff writers
Posted on 01 Dec 2020
Myeloid malignancies are clonal diseases of hematopoietic stem or progenitor cells. More...
Myeloid malignancies, including acute myeloid leukemia (AML), arise from the expansion of these hematopoietic stem and progenitor cells that acquire somatic mutations.

Bulk molecular profiling has suggested that mutations are acquired in a stepwise fashion: mutant genes with high variant allele frequencies appear early in leukemogenesis, and mutations with lower variant allele frequencies are thought to be acquired later.

A large team of Hematologist and Oncologists at the Memorial Sloan Kettering Cancer Center (New York, NY, USA) delineated the clonal framework of myeloid malignancies. They performed single-cell mutational profiling on 146 samples from 123 patients, mapping clonal trajectories for each sample and observing mutations that combined to promote clonal expansion and dominance. The investigators also combined protein expression with mutational analysis to map somatic genotype and clonal architecture with immunophenotype. Overall, they said, these findings provided insights into the pathogenesis of myeloid transformation and how clonal complexity evolves with disease progression.

The team used a custom amplicon panel from Mission Bio (South San Francisco, CA, USA) covering 31 frequently mutated genes, to perform single-cell sequencing. They sequenced 740,529 cells from 146 samples from patients at diagnosis and/or relapse. The most common mutations they identified were in DNMT3A, TET2, NPM1, and FLT3. They next investigated disease subtypes, subdividing the cases into samples with epigenetic mutations, samples with signaling mutations, samples without epigenetic mutations, and samples with epigenetic and co-mutated signaling effectors. Of the 80 AML samples with epigenetic mutations, nearly 53% harbored mutations in more than one epigenetic modifier. In nearly all cases, epigenetic regulator mutations were in the same clone, and in 81% of cases the co-occurring mutations were within the dominant clone, suggesting cooperativity between epigenetic mutations.

The number of mutations per sample was significantly higher in AML than in myeloproliferative neoplasms (MPN) and in MPN than in clonal hematopoiesis (CH). The increase in mutations per sample was more pronounced in cases of AML with signaling effector mutations, specifically those in RAS and FLT3. The investigators were then able to identify gene-specific contributions to clonal expansion, finding that IDH2, NPM1, and JAK2 mutations were nearly always present in the dominant clone, whereas FLT3 and RAS mutations were present only in minor subclones in some patients, and in dominant clones in others. In four out of six patients in whom the disease transformed from MPN to AML, they observed a significant alteration in clonal architecture, with emergence of new dominant clones.

The authors concluded that the data suggested that myeloid malignancies manifest as a complex ecosystem of clones that evolves over time, and that scDNA-seq gives a glimpse into this milieu that is not seen with conventional bulk sequencing. Studies of clonal architecture at a single-cell level give us insights into how clonal complexity contributes to the pathogenesis of myeloid transformation. The study was published on October 28, 2020 in the journal Nature.

Related Links:
Memorial Sloan Kettering Cancer Center
Mission Bio



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.